P. Sharma, K. Wagner, J. Wolchok, and J. Allison, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nature Reviews Cancer, vol.208, issue.11, pp.805-817, 2011.
DOI : 10.1084/jem.20100619

URL : http://europepmc.org/articles/pmc3426440?pdf=render

E. Buchbinder and A. Desai, CTLA-4 and PD-1 Pathways, American Journal of Clinical Oncology, vol.39, issue.1, pp.98-106, 2016.
DOI : 10.1097/COC.0000000000000239

URL : http://doi.org/10.1097/coc.0000000000000239

J. Guan, K. Lim, T. Mekhail, and C. Chang, Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers, Archives of Pathology & Laboratory Medicine, vol.141, issue.6, pp.851-61, 2017.
DOI : 10.5858/arpa.2016-0361-RA

URL : http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2016-0361-RA

J. He, Y. Hu, M. Hu, and B. Li, Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non, Small Cell Lung Cancer. Sci Rep, vol.5, pp.13110-13115, 2015.

D. Chen, B. Irving, and F. Hodi, Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clinical Cancer Research, vol.18, issue.24, pp.6580-6587, 2012.
DOI : 10.1158/1078-0432.CCR-12-1362

URL : http://clincancerres.aacrjournals.org/content/clincanres/18/24/6580.full.pdf

E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian et al., Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015.
DOI : 10.1056/NEJMoa1501824

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. Grob, C. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015.
DOI : 10.1056/NEJMoa1504030

URL : http://www.zora.uzh.ch/id/eprint/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf

R. Motzer, B. Escudier, D. Mcdermott, S. George, H. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015.
DOI : 10.1056/NEJMoa1510665

URL : http://europepmc.org/articles/pmc5719487?pdf=render

S. Antonia, J. López-martin, J. Bendell, P. Ott, M. Taylor et al., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.7, pp.883-95, 2016.
DOI : 10.1016/S1470-2045(16)30098-5

URL : http://eprints.gla.ac.uk/118215/13/118215.pdf

J. Weber, D. Angelo, S. Minor, D. Hodi, F. Gutzmer et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015.
DOI : 10.1016/S1470-2045(15)70076-8

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. Grob, C. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015.
DOI : 10.1056/NEJMoa1504030

URL : http://www.zora.uzh.ch/id/eprint/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf

H. Borghaei, L. Paz-ares, L. Horn, D. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015.
DOI : 10.1056/NEJMoa1507643

URL : http://europepmc.org/articles/pmc5705936?pdf=render

C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/hal-00699117

J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2015.
DOI : 10.1056/NEJMoa1504627

S. Antonia, J. López-martin, J. Bendell, P. Ott, M. Taylor et al., Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, The Lancet Oncology, vol.17, issue.7, pp.883-95, 2016.
DOI : 10.1016/S1470-2045(16)30098-5

URL : http://eprints.gla.ac.uk/118215/13/118215.pdf

C. Robert, J. Schachter, G. Long, A. Arance, J. Grob et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015.
DOI : 10.1056/NEJMoa1503093

R. Herbst, P. Baas, D. Kim, E. Felip, J. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-50, 2016.
DOI : 10.1016/S0140-6736(15)01281-7

, Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) -Full Text View -ClinicalTrials.gov n.d. https://clinicaltrials.gov/ct2/show, p.2252042, 2017.

M. Reck, D. Rodríguez-abreu, A. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016.
DOI : 10.1056/NEJMoa1606774

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, pp.1837-1883, 2016.
DOI : 10.1016/S0140-6736(16)00587-0

J. Hoffman-censits, P. Grivas, M. Van-der-heijden, R. Dreicer, Y. Loriot et al., IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)., Journal of Clinical Oncology, vol.34, issue.2_suppl, pp.355-355, 2016.
DOI : 10.1200/jco.2016.34.2_suppl.355

S. Gandini, D. Massi, and M. Mandalà, PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis, Critical Reviews in Oncology/Hematology, vol.100, pp.88-98, 2016.
DOI : 10.1016/j.critrevonc.2016.02.001

P. Sharma and J. Allison, The future of immune checkpoint therapy, Science, vol.19, issue.5, pp.56-61, 2015.
DOI : 10.1158/1078-0432.CCR-12-1630

J. Powderly, H. Koeppen, F. Hodi, J. Sosman, S. Gettinger et al., Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study [abstract], J Clin Oncol, vol.31, pp.3001-3001, 2013.

M. Ilie, E. Long-mira, C. Bence, C. Butori, S. Lassalle et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.7, issue.1, pp.147-53, 2016.
DOI : 10.4103/0973-1482.163837

A. Midha, A. Sharpe, M. Scott, J. Walker, K. Shi et al., PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age [abstract] Diagnostic PD-L1 immunohistochemistry in NSCLC: Results of the first German harmonization study [abstract] Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma, J Clin Oncol J Clin Oncol Appl Immunohistochem Mol Morphol Bioconjug Chem, vol.343427, issue.15, pp.3025-3052, 2016.

R. Dronca, Frequency of certain immune cells in blood may predict metastatic melanoma response to Pembrolizumab CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

A. Ngiow, S. Young, A. Jacquelot, N. Yamazaki, T. Enot et al., T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1, Release-Detail.aspx?ItemID=759 [31], pp.3800-3811, 2015.
DOI : 10.1158/0008-5472.CAN-15-1082

URL : http://cancerres.aacrjournals.org/content/canres/75/18/3800.full.pdf

M. Teng, S. Ngiow, A. Ribas, and M. Smyth, Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Research, vol.75, issue.11
DOI : 10.1158/0008-5472.CAN-15-0255

URL : http://cancerres.aacrjournals.org/content/canres/75/11/2139.full.pdf

, Cancer Res, vol.75, pp.2139-2184, 2015.

P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-71, 2014.
DOI : 10.1158/1078-0432.CCR-09-1624

T. Choueiri, M. Fishman, B. Escudier, D. Mcdermott, C. Drake et al., Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma, Clinical Cancer Research, vol.22, issue.22, pp.5461-71, 2016.
DOI : 10.1158/1078-0432.CCR-15-2839

R. Vilain, A. Menzies, J. Wilmott, H. Kakavand, J. Madore et al., Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma, Clinical Cancer Research, vol.23, issue.17, pp.5024-5057, 2017.
DOI : 10.1158/1078-0432.CCR-16-0698

W. Wang, D. Yu, A. Sarnaik, Y. B. Hall, M. Morelli et al., Biomarkers on melanoma patient T Cells associated with ipilimumab treatment, Journal of Translational Medicine, vol.10, issue.1, p.146, 2012.
DOI : 10.1002/eji.200939261

D. Giacomo, A. Calabrò, L. Danielli, R. Fonsatti, E. Bertocci et al., Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10??mg/kg within an expanded access programme, Cancer Immunology, Immunotherapy, vol.91, issue.Suppl 7, pp.1021-1029, 2013.
DOI : 10.1002/jso.20329

D. Giacomo, A. Ascierto, P. Queirolo, P. Pilla, L. Ridolfi et al., Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study, Annals of Oncology, vol.32, issue.5, pp.798-803, 2015.
DOI : 10.3109/07357907.2014.885984

N. Tang, D. Shen, Y. Sun, J. Wen, S. Wolchok et al., Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy, Cancer Immunology Research, vol.1, issue.4, pp.229-263, 2013.
DOI : 10.1158/2326-6066.CIR-13-0020

S. Funt, A. Charen, E. Yusko, M. Vignali, S. Benzeno et al., Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab [abstract] Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis, J Clin Oncol PLoS Med, vol.3414, issue.15, pp.1002309-1002351, 2016.

K. Karwacz, C. Bricogne, D. Macdonald, F. Arce, C. Bennett et al., T cells, EMBO Molecular Medicine, vol.185, issue.10, pp.581-92, 2011.
DOI : 10.4049/jimmunol.1001821

D. Escors, C. Bricogne, F. Arce, G. Kochan, and K. Karwacz, On the Mechanism of T cell receptor downmodulation and its physiological significance, The Journal of Bioscience and Medicine, vol.1, issue.1, 2011.
DOI : 10.5780/jbm2011.5

M. Postow, M. Manuel, P. Wong, J. Yuan, Z. Dong et al., Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma, Journal for ImmunoTherapy of Cancer, vol.19, issue.3, pp.23-45, 2015.
DOI : 10.1038/nm.3100

URL : https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-015-0070-4?site=jitc.biomedcentral.com

L. Robert, J. Tsoi, X. Wang, R. Emerson, B. Homet et al., CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire, Clinical Cancer Research, vol.20, issue.9, pp.2424-2456, 2014.
DOI : 10.1158/1078-0432.CCR-13-2648

URL : http://clincancerres.aacrjournals.org/content/clincanres/20/9/2424.full.pdf

D. Oh, J. Cham, L. Zhang, G. Fong, M. Klinger et al., Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients [abstract], J Clin Oncol, vol.3447, 2016.
DOI : 10.1158/1538-7445.am2016-4362

P. Ferrucci, S. Gandini, A. Battaglia, S. Alfieri, D. Giacomo et al., Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients, British Journal of Cancer, vol.102, issue.12
DOI : 10.1093/annonc/mdt161

URL : http://www.nature.com/bjc/journal/v112/n12/pdf/bjc2015180a.pdf

M. Moschetta, B. Kasenda, G. Mak, M. Voskoboynik, N. Martynyuk et al., Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors [abstract] Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy, Br J Cancer J Clin Oncol Oncotarget, vol.112347, pp.1904-1077404, 2015.

M. Zibelman, J. Judd, E. Handorf, O. Neill, J. Bentota et al., Association of eosinophila with efficacy in non-melanoma patients treated with programmed death 1 inhibitors [abstract], J Clin Oncol, vol.3451, 2016.

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel et al., Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Annals of Oncology, vol.62, issue.6, pp.1697-703, 2013.
DOI : 10.1111/j.1365-3083.2005.01682.x

D. Le, J. Uram, H. Wang, B. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2529, 2015.
DOI : 10.1056/NEJMoa1500596

URL : http://europepmc.org/articles/pmc4481136?pdf=render

A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J. Zaretsky et al., Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma, New England Journal of Medicine, vol.371, issue.23, pp.2189-99, 2014.
DOI : 10.1056/NEJMoa1406498

N. Rizvi, M. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.105, issue.51, pp.124-132, 2015.
DOI : 10.1073/pnas.0810114105

URL : http://europepmc.org/articles/pmc4993154?pdf=render

Y. Chae, J. Anker, N. Mohindra, J. Kaplan, S. Chandra et al., Mutational burden and activated T cell infiltration in lung squamous cell carcinomas with DNA repair mutations [abstract], J Clin Oncol, vol.3456, 2016.

P. Tsantoulis, L. Hill, S. Walker, P. Wirapati, D. Graham et al., Association of a specific innate immune response to DNA damage with DNA repair deficient colorectal cancers [abstract] Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: a TCGA pan-cancer analysis [abstract] Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types [abstract], J Clin Oncol J Clin Oncol J Clin Oncol, vol.3457343459, 2016.

W. Hugo, J. Zaretsky, L. Sun, C. Song, B. Moreno et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, vol.165, issue.1, pp.35-44, 2016.
DOI : 10.1016/j.cell.2016.02.065

URL : https://doi.org/10.1016/j.cell.2016.02.065

N. Riaz, J. Havel, S. Kendall, V. Makarov, L. Walsh et al., Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy, Nature Genetics, vol.48, issue.11, pp.1327-1336, 2016.
DOI : 10.1007/s00251-015-0873-y

URL : http://europepmc.org/articles/pmc5553281?pdf=render

A. Snyder, E. Pamer, and W. J. Immunotherapy, Could microbial therapy boost cancer immunotherapy?, Science, vol.368, issue.7, pp.1031-1033, 2015.
DOI : 10.1056/NEJMoa1205037

A. Sivan, L. Corrales, N. Hubert, J. Williams, K. Aquino-michaels et al., Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, vol.68, issue.3, pp.1084-1093, 2015.
DOI : 10.1111/j.1574-6941.2009.00671.x

URL : http://europepmc.org/articles/pmc4873287?pdf=render

M. Vétizou, J. Pitt, R. Daillère, P. Lepage, N. Waldschmitt et al., Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, vol.17, issue.2, pp.1079-84, 2015.
DOI : 10.1016/j.anaerobe.2011.03.004

V. Rubio-godoy, V. Dutoit, Y. Zhao, R. Simon, P. Guillaume et al., Positional scanningsynthetic peptide library-based analysis of self-and pathogen-derived peptide cross-reactivity with tumorreactive Melan-A-specific CTL, J Immunol Baltim Md, vol.65169, pp.5696-707, 1950.
DOI : 10.4049/jimmunol.169.10.5696

URL : http://www.jimmunol.org/content/jimmunol/169/10/5696.full.pdf

J. Wang, C. Chang, J. Lin, L. Wu, L. Chuang et al., Infection, antibiotic therapy and risk of colorectal cancer: A nationwide nested case-control study in patients with Type 2 diabetes mellitus, International Journal of Cancer, vol.53, issue.4, pp.956-67, 2014.
DOI : 10.1093/cid/cir609

M. Vétizou, R. Daillère, and L. Zitvogel, R??le du microbiote intestinal dans la r??ponse aux th??rapies anti-tumorales, Biologie Aujourd'hui, vol.8, issue.1, pp.51-67, 2017.
DOI : 10.1038/nri2216

J. Massagué, TGF?? in Cancer, Cell, vol.134, issue.2, pp.215-245, 2008.
DOI : 10.1016/j.cell.2008.07.001

V. Gupta, T. Davancaze, J. Good, N. Kalia, and M. Anderson, platform, Bioanalysis, vol.14, issue.23, pp.2415-2428, 2016.
DOI : 10.1186/s12014-015-9101-x

URL : https://hal.archives-ouvertes.fr/inria-00494120

O. Hamid, H. Schmidt, A. Nissan, L. Ridolfi, S. Aamdal et al., A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, Journal of Translational Medicine, vol.9, issue.1, pp.204-71, 2011.
DOI : 10.1097/CJI.0b013e31817fd8f3

S. Hwang, N. Chung, J. Chan, and C. Lin, Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines, Cell Research, vol.196, issue.3, pp.167-75, 2005.
DOI : 10.1084/jem.20020052

K. Singer, E. Gottfried, M. Kreutz, and A. Mackensen, Suppression of T-cell responses by tumor metabolites, Cancer Immunology, Immunotherapy, vol.10, issue.8, pp.425-456, 2011.
DOI : 10.1158/1078-0432.CCR-04-0039

M. Santarpia, M. González-cao, S. Viteri, N. Karachaliou, G. Altavilla et al., Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role, Transl Lung Cancer Res, vol.4, pp.728-770, 2015.